Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Marker Therapeutics Inc
MRKR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.04
-0.03
-2.8%
Últ. Act.: Oct 23, 10:46 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Marker Therapeutics Financials
Marker Therapeutics (MRKR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Marker Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 60 percent increase over losses of $(0.40) per share from
Benzinga Newsdesk
PRO
Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.47) by 81.68 percent. This is a 79.29 percent increase over losses of $(0.42) per share
Benzinga Newsdesk
PRO
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share
Benzinga Newsdesk
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings
Avi Kapoor
PRO
Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat
Benzinga Newsdesk
PRO
Marker Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.43) Estimate, Sales $1.17M Up From $762.66K YoY
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.43) by 41.86 percent. The company reported $1.17 million in sales this quarter. This is a
Benzinga Newsdesk
